Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
A phase 2 trial of Enzalutamide in prostate cancer, run by Syntrix Biosystems, Inc., now recruiting.
Overview
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer is a phase 2 interventional study registered as NCT06228053 by Syntrix Biosystems, Inc., with 53 participants planned, started 2024-11-18 and due to reach its primary completion in 2027-06-30. Interventions recorded: SX-682, Enzalutamide. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAn Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo
Shares Enzalutamide, Prostate cancer.
- TrialZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Shares Enzalutamide, Prostate cancer.
- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Enzalutamide, Prostate cancer.
- TrialA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Shares Enzalutamide, Prostate cancer.
- TrialThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En
Shares Enzalutamide, Prostate cancer.
- TrialEMBARK
Shares Enzalutamide, Prostate cancer.
- TrialARCHES
Shares Enzalutamide, Prostate cancer.
- TrialA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Shares Enzalutamide, Prostate cancer.